Pandemic expert calls for manufacturing coronavirus vaccines before they're proven to work

Teams around the world are racing to develop a vaccine for the COVID-19 coronavirus in the hopes that a successful one will lead the charge in normalizing life. But there are likely to be failures along the way — that's just the nature of vaccine development, Richard Hatchett, the CEO of the Norway-based Coalition for Epidemic Preparedness Innovations, told Stat News. Still, Hatchett believes it's important to begin production of some potential vaccines before they're proven to work.
Hatchett said if the hope is to get vaccines out as quickly as possible while also minimizing health safety risks, "we're going to have to take an awful lot of financial risk." That includes "investing in manufacturing capacity for everything" and "even beginning full-scale manufacturing before we know if the vaccine even works." The comments echo those previously made by Bill Gates.
Stocking up on vaccines in the meantime would theoretically speed up the process of administering vaccinations once they have the green light, allowing more people to protect themselves from COVID-19 in a shortened timeframe. But it will take a lot of resources, Hatchett said, meaning governments will need to shell out for it, which he expects will happen. "That's talking tens of billions of dollars if you include the cost of manufacturing hundreds of millions or billions of doses," he said. Read more at Stat News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
How Canadian tariffs could impact tourism to the US
In the Spotlight Canadians represent the largest group of foreign visitors to the United States. But they may soon stop visiting.
By Justin Klawans, The Week US Published
-
Entitlements: DOGE goes after Social Security
Feature Elon Musk is pushing false claims about Social Security fraud
By The Week US Published
-
The Week contest: Amazon Bond
Puzzles and Quizzes
By The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published